Ayuda
Ir al contenido

Dialnet


New product intros [anakinra (new indication), bamlanivimab, baricitinib (new indication), BBIBP-CorV, belimumab (new indication), calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate (new formulation), casirivimab/imdevimab, ensartinib hydrochloride, favipiravir (new indication), Gam-COVID-Vac, inactivated SARS-CoV-2 vaccine, loteprednol etabonate (new indication), lumasiran (first-in-class), mRNA-1273, rilonacept (new indication), tozinameran].

  • Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 57, Nº. 2, 2021, págs. 179-182
  • Idioma: inglés
  • Texto completo no disponible (Saber más ...)
  • Resumen
    • [anakinra (new indication), bamlanivimab, baricitinib (new indication), BBIBP-CorV, belimumab (new indication), calcium oxybate/magnesium oxybate/potassium oxybate/sodium oxybate (new formulation), casirivimab/imdevimab, ensartinib hydrochloride, favipiravir (new indication), Gam-COVID-Vac, inactivated SARS-CoV-2 vaccine, loteprednol etabonate (new indication), lumasiran (first-in-class), mRNA-1273, rilonacept (new indication), tozinameran].


Fundación Dialnet

Dialnet Plus

  • Más información sobre Dialnet Plus

Opciones de compartir

Opciones de entorno